DrugPatentWatch Database Preview
Cetuximab - Biologic Drug Details
» See Plans and Pricing
Summary for cetuximab
| Tradenames: | 1 |
| Patents: | 654 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for cetuximab |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for cetuximab |
Recent Clinical Trials for cetuximab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Dutch Cancer Society | Phase 2 |
| Weill Medical College of Cornell University | Phase 2 |
| Oncolys BioPharma Inc | Phase 2 |
Recent Litigation for cetuximab
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Ravgen, Inc. v. Progenity, Inc. | 2020-12-20 |
| Ravgen, Inc. v. Myriad Genetics, Inc. | 2020-12-20 |
| Ravgen, Inc. v. Ariosa Diagnostics, Inc. | 2020-12-02 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| GEMoaB Monoclonals GmbH | 2019-12-20 |
| 2018-09-14 | |
| Forty Seven, Inc. | 2018-01-08 |
Pharmacology for cetuximab
| Mechanism of Action | HER1 Antagonists |
Company Disclosures: US Patents for cetuximab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | Rhone-Poulenc Rorer International (Holdings), Inc. (Greenville, DE) | 2018-04-17 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for cetuximab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) | 2032-09-12 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | Yeda Research and Development Co. Ltd. (Rehovot, IL) | 2034-09-08 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for cetuximab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2009128997 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2016022956 | Start Trial |
| China | 103372221 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for cetuximab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015000061 | Germany | Start Trial | PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
| 2015031 | Lithuania | Start Trial | PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
| 2015000013 | Germany | Start Trial | PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
